Lymphoma drug Zevalin may be an important drug for 2012! It did really well in a recent study of patients undergoing bone marrow transplant to treat an aggressive form of the blood cancer. Patients who took a Zevalin combination had a higher two year survival rate of 91%! Patients with an "intermediate level of the disease" lived significantly longer without seeing the cancer worsen. Zevalin will be studied further in larger clinical trials because of these promising results. It is already approved in the U.S. for certain forms on non-Hodgkin's lymphoma.
If interested in reading more on this story: